NPHLA Intelligence
Clinical Trial Watch
Trials NPHLA follows, synchronised from ClinicalTrials.gov. We flag what matters (new registrations, changes in status and newly posted results) and ignore routine record edits. Every therapy in a trial is investigational.
- Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults
Korea United Pharm. Inc.. Conditions: Bioequivalence; Pharmacokinetics. Investigational — not approved for the use studied.
- A Phase I Study to Evaluate the Food Effect on Ecnoglutide Tablet
Hangzhou Sciwind Biosciences Co., Ltd.. Conditions: Food Effect in Healthy Volunteers; Weight Management. Investigational — not approved for the use studied.
- Effects of a Gut-Active Peptide That Stimulates GLP-1 Release on Appetite and Satiety in Healthy Adults With Overweight
Lembas. Conditions: Appetite and Hunger, Suppression; Satiety and Appetite; Weight Change; Gastrointestinal Symptoms; Body Composition. Investigational — not approved for the use studied.
- AMBITION 3: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
Novo Nordisk A/S. Conditions: Type 2 Diabetes. Investigational — not approved for the use studied.
- AMBITION4: A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
Novo Nordisk A/S. Conditions: Diabetes Mellitus, Type 2. Investigational — not approved for the use studied.
- A Retrospective Study to Assess Patient-Reported Treatment Experience With Over-the-Counter Analgesic Products
HALEON. Conditions: Pain. Investigational — not approved for the use studied.
- PRESERVE GLP-1: Lifestyle Strategies to Preserve Muscle and Reduce Cardiovascular Risk in Adults With Obesity Using GLP-1 Receptor Agonists
University of Florida. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- Changes in Body Composition and Muscle Composition After GLP-1 Receptor Agonist Therapy in Patients With Obesity
Ulsan University Hospital. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight
Pfizer. Conditions: Urinary Incontinence, Stress; Overweight and/or Obesity. Investigational — not approved for the use studied.
- RESIST-EXHALE: Breath Acetone During Tirzepatide Treatment and Resistance Training in Adults With Obesity
Technical University of Munich. Conditions: Obesity (Disorder). Investigational — not approved for the use studied.
- RESIST-EXPLORE: Molecular and Microbiome Changes During Tirzepatide Treatment and Resistance Training in Obesity
Technical University of Munich. Conditions: Obesity (BMI Equal to or >30). Investigational — not approved for the use studied.
- ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease
Boehringer Ingelheim. Conditions: Obesity; Metabolic Dysfunction-associated Steatotic Liver Disease. Investigational — not approved for the use studied.
- A Study to Evaluate the Safety and Efficacy of Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
Hangzhou Sciwind Biosciences Co., Ltd.. Conditions: Overweight , Obesity; Weight Management. Investigational — not approved for the use studied.
- CLEAR-GLP1: 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor
Portuguese Oncology Institute, Coimbra. Conditions: Retained Gastric Content; Delayed Gastric Emptying; Obesity; Type 2 Diabetes Mellitus (DM). Investigational — not approved for the use studied.
- RESIST-MIND: Functional, Cognitive, and Behavioral Correlates of Resistance Training During Tirzepatide-Induced Weight Loss
Technical University of Munich. Conditions: Obesity (Disorder). Investigational — not approved for the use studied.
- COMPACT: Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes
German Diabetes Center. Conditions: Type 2 Diabetes (T2DM); Obesity & Overweight; Sarcopenia. Investigational — not approved for the use studied.
- Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes
Peking University People's Hospital. Conditions: Type 1 Diabetes. Investigational — not approved for the use studied.
- A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Shenzhen Salubris Pharmaceuticals Co., Ltd.. Conditions: Type 2 Diabetes Mellitus (T2DM); Type 2 Diabetes; T2DM. Investigational — not approved for the use studied.
- VITAL-H: Validation & Intervention Testing for Aging, Longevity and Healthspan
The University of Texas Health Science Center at San Antonio. Conditions: Aging; Functional Decline. Investigational — not approved for the use studied.
- MEASURE: Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Boston Scientific Corporation. Conditions: Type 2 Diabetes Mellitus (T2D); Obesity (BMI>30). Investigational — not approved for the use studied.
- SPOT-DM: Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
University Health Network, Toronto. Conditions: Kidney Transplant Recipient. Investigational — not approved for the use studied.
- REDEFINE: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
Novo Nordisk A/S. Conditions: Hypertension; Obesity. Investigational — not approved for the use studied.
- Enith-MACE: A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease
Hoffmann-La Roche. Conditions: Overweight; Obesity; Cardiovascular Disease. Investigational — not approved for the use studied.
- UNISHAPE-OSA-1: UBT251 Injection Phase Ⅲ Study (OSA-NPAP)
The United Bio-Technology (Hengqin) Co., Ltd.. Conditions: Obstructive Sleep Apnea, Obesity. Investigational — not approved for the use studied.
- A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- AMPLIFY-1: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
Eli Lilly and Company. Conditions: Obesity. Investigational — not approved for the use studied.
- OFF-RAMP: Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
Jing Luo. Conditions: Obesity & Overweight; Cardiometabolic Health Indicators. Investigational — not approved for the use studied.
- ERCG vs Intensive Lifestyle Intervention for Weight Regain After GLP-1 RA Discontinuation
Affiliated Hospital to Academy of Military Medical Sciences. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- WISPER: Semaglutide for Weight Management During Hormone Therapy for Early Breast Cancer
Aarhus University Hospital. Conditions: Breast Cancer (Early Breast Cancer); Obesity. Investigational — not approved for the use studied.
- BOLD: Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
Erin Mauney. Conditions: Pediatric Obesity; Obesity. Investigational — not approved for the use studied.
- TIRZE-PAP: Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea
Woolcock Institute of Medical Research. Conditions: Sleep Apnoea; Obesity & Overweight; Sleep Apnea Syndrome, Obstructive. Investigational — not approved for the use studied.
- SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight
Boehringer Ingelheim. Conditions: Obesity. Investigational — not approved for the use studied.
- TAP: Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
University of Wisconsin, Madison. Conditions: GLP-1; Alcohol. Investigational — not approved for the use studied.
- Efficacy, Safety, and Treatment Satisfaction of Once-Weekly Tirzepatide in Obese Type 2 Diabetic Patients
Akhtar Saeed Medical and Dental College. Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight. Investigational — not approved for the use studied.
- H24LEAP2: Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity
University Hospital, Gentofte, Copenhagen. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
Boehringer Ingelheim. Conditions: Obesity. Investigational — not approved for the use studied.
- RISE-1: Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals. Conditions: Overweight or Obesity Without Diabetes. Investigational — not approved for the use studied.
- Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Mayo Clinic. Conditions: Obese Adults. Investigational — not approved for the use studied.
- ENI-SPIRE-2: A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
Hoffmann-La Roche. Conditions: Type 2 Diabetes Mellitus. Investigational — not approved for the use studied.
- GUT BOOST: Supplementation of Gut-brain Axis (GLP-1)-Activating Carbohydrates for Increasing Satiety in Adolescents With Obesity
Indiana University. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity
University of Yaounde 1. Conditions: Obesity & Overweight. Investigational — not approved for the use studied.
- TRIBUTE-PK: Real-World Outcomes of Tirzepatide in Pakistani Adults With Obesity, Prediabetes, and Type 2 Diabetes
Universiti Sains Malaysia. Conditions: Prediabetes or Overweight; Obesity Type 2 Diabetes Mellitus; Obesity & Overweight. Investigational — not approved for the use studied.
- STAY SEC PsO: A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
Novartis Pharmaceuticals. Conditions: Plaque Psoriasis. Investigational — not approved for the use studied.
- GLOW: GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
University of Minnesota. Conditions: Obesity, Childhood. Investigational — not approved for the use studied.
- S-CUD: Semaglutide for the Treatment of Cannabis Use Disorder
Massachusetts General Hospital. Conditions: Cannabis Use Disorder; Cue-reactivity. Investigational — not approved for the use studied.
- SHAPED-AU: Semaglutide Health Outcomes and Patient Adherence in Australia
Novo Nordisk A/S. Conditions: Overweight; Obesity. Investigational — not approved for the use studied.
- Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia
Stanford University. Conditions: Post-Bariatric Hypoglycemia. Investigational — not approved for the use studied.
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
Viking Therapeutics, Inc.. Conditions: Weight Loss. Investigational — not approved for the use studied.
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
Viking Therapeutics, Inc.. Conditions: Weight Loss. Investigational — not approved for the use studied.
- Long-Term Effects of Semaglutide on Body Composition and Performance in Running
Morten Hostrup, PhD. Conditions: Caloric Restriction; Body Composition; Performance. Investigational — not approved for the use studied.
- Yeast Protein Supplementation and Muscle Preservation During GLP-1RA-Induced Weight Loss
Huazhong University of Science and Technology. Conditions: Overweight and Obesity in Adults Receiving GLP-1RA Treatment. Investigational — not approved for the use studied.
- Short Term Effects of Semaglutide on Body Composition and Performance
Morten Hostrup, PhD. Conditions: Caloric Restriction; Body Composition; Performance. Investigational — not approved for the use studied.
- AFTER-GLP: Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
Tufts University. Conditions: Weight Maintenance. Investigational — not approved for the use studied.
- Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients
Nanjing First Hospital, Nanjing Medical University. Conditions: Obesity / Overweight. Investigational — not approved for the use studied.
- GLOW: GLP-1 Impacts on Weight Management
University of California, San Francisco. Conditions: Weight Management; Disordered Eating Behaviors. Investigational — not approved for the use studied.
- ATTAIN-CN: A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
Eli Lilly and Company. Conditions: Obesity; Overweight. Investigational — not approved for the use studied.
- Tirzepatide for the Treatment of Cannabis Use Disorder
Brigham and Women's Hospital. Conditions: Cannabis Use Disorder. Investigational — not approved for the use studied.
- Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
Dr. Md. Alimur Reza. Conditions: Obesity. Investigational — not approved for the use studied.
- PIVOT: Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access
Kristin Clemens. Conditions: Obesity; Chronic Kidney Disease; Chronic Renal Disease; CKD. Investigational — not approved for the use studied.
- Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE)
General Committee of Teaching Hospitals and Institutes, Egypt. Conditions: Morbid Obesity. Investigational — not approved for the use studied.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Trial listings are not recommendations to enrol or prescribe.